Randomized Phase III Trial Exploring the Use of LongActing Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial

Imagem de Miniatura
Arquivos
art_HOFF_Randomized_Phase_III_Trial_Exploring_the_Use_of_2014.PDF (146.72 KB)
Citações na Scopus
37
Tipo de produção
article
Data de publicação
2014
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIOMED CENTRAL LTD
Autores
BARRIOS, Carlos H.
GIGLIO, Auro del
COUTINHO, Anelisa K.
ANDRADE, Aline C.
DUTRA, Carolina
FORONES, Nora M.
CORREA, Mariangela
PORTELLA, Maria do Socorro O.
Citação
JOURNAL OF CLINICAL ONCOLOGY, v.32, n.10, p.1006-1011, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose Chemotherapy-induced diarrhea (CID) is a relatively common adverse event in the treatment of patients with colorectal cancer. The LAR for Chemotherapy-Induced Diarrhea (LARCID) trial evaluated the efficacy and safety of long-acting release octreotide (octreotide LAR) for the prevention of CID in this population. Patients and Methods Patients with colorectal cancer starting adjuvant or first-line treatment with a chemotherapy combination containing fluorouracil, capecitabine, and/or irinotecan were randomly assigned to receive octreotide LAR 30 mg intramuscularly every 4 weeks (experimental arm) or the physician's treatment of choice in case of diarrhea (control arm). Results A total of 139 patients were randomly assigned, most of whom received fluorouracil- and oxaliplatin-containing chemotherapy regimens. The rate of diarrhea was 76.1% in the experimental group (n = 68) and 78.9% in the control group (n = 71). Treatment with octreotide LAR did not prevent or reduce the severity of CID. Treatment choices for diarrhea management included loperamide in the majority of patients. No benefit from octreotide LAR was identified in terms of need for diarrhea treatment, opioids, or intravenous hydration or in the rate of hospitalization or quality of life. Conclusion This study could not prove the efficacy of octreotide LAR in the prevention of CID.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/15986
Referências
  1. Bajetta E, 2004, CANCER, V100, P279, DOI 10.1002/cncr.11910
  2. Barbounis V, 2001, SUPPORT CARE CANCER, V9, P258, DOI 10.1007/s005200000220
  3. Benson AB, 2004, J CLIN ONCOL, V22, P2918, DOI 10.1200/jco.2004.04.132
  4. Borner MM, 2005, ANN ONCOL, V16, P282, DOI 10.1093/annonc/mdi047
  5. Cartwright Thomas, 2005, Clin Colorectal Cancer, V5, P50, DOI 10.3816/CCC.2005.n.016
  6. CASCINU S, 1992, EUR J CANCER, V28A, P482
  7. CASCINU S, 1993, J CLIN ONCOL, V11, P148
  8. Chen TL, 2000, J CLIN PHARMACOL, V40, P475, DOI 10.1177/00912700022009242
  9. Classen J, STRAHLENTHER ONKOL
  10. Colucci G, 2005, J CLIN ONCOL, V23, P4866, DOI 10.1200/JCO.2005.07.113
  11. Fuchs CS, 2007, J CLIN ONCOL, V25, P4779, DOI 10.1200/JCO.2007.11.3357
  12. GEBBIA V, 1993, ANTI-CANCER DRUG, V4, P443, DOI 10.1097/00001813-199308000-00004
  13. GORDEN P, 1989, ANN INTERN MED, V110, P35
  14. Goumas P, 1998, ONCOLOGIST, V3, P50
  15. Hoff PM, 2001, J CLIN ONCOL, V19, P2282
  16. Ippoliti C, 1997, J CLIN ONCOL, V15, P3350
  17. Ippoliti C, 1998, Oncol Nurs Forum, V25, P873
  18. Kim TW, 2005, ACTA ONCOL, V44, P230, DOI 10.1080/02841860510029590
  19. Maroun J A, 2007, Curr Oncol, V14, P13, DOI 10.3747/co.2007.96
  20. Martenson JA, 2008, J CLIN ONCOL, V26, P5248, DOI 10.1200/JCO.2008.17.1546
  21. National Comprehensive Network, 2011, MET COL CANC NCCN CL
  22. Pro B, 2001, INVEST NEW DRUG, V19, P341, DOI 10.1023/A:1010678214152
  23. Rosenoff S, 2004, SUPPORT CARE CANCER, V12, P561, DOI 10.1007/s00520-003-0507-z
  24. Rosenoff SH, 2004, EUR J CANCER CARE, V13, P380, DOI 10.1111/j.1365-2354.2004.00511.x
  25. Rosenoff Stephen H, 2006, J Support Oncol, V4, P289
  26. Rothenberg ML, 2001, J CLIN ONCOL, V19, P3801
  27. Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302
  28. Sastre J, 2005, J CLIN ONCOL, V23, P3545, DOI 10.1200/JCO.2005.03.004
  29. Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
  30. Townsley CA, 2006, BRIT J CANCER, V94, P1136, DOI 10.1038/sj.bjc.6603055
  31. Wadler S, 1998, J CLIN ONCOL, V16, P3169
  32. Yavuz MN, 2002, INT J RADIAT ONCOL, V54, P195, DOI 10.1016/S0360-3016(02)02870-5
  33. Zachariah B, 2010, JNCI-J NATL CANCER I, V102, P547, DOI 10.1093/jnci/djq063
  34. Zidan J, 2001, ANN ONCOL, V12, P227, DOI 10.1023/A:1008372228462

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03